Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -37.05% is 112% below its 5-year average of -17.50%, around the middle of its 5-year range (-118.52%–-0.86%).
As of the fiscal period ended Tuesday, June 30, 2026. 60.10% above its 12-month average of -92.85%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -37.05%.
RETURN ON EQUITY (ROE)
-37.05%
RETURN ON EQUITY (ROE) AVG TTM
-92.85%
RETURN ON EQUITY (ROE) AVG 3Y
-51.69%
RETURN ON EQUITY (ROE) AVG 5Y
-17.50%
RETURN ON EQUITY (ROE) AVG 10Y
-7.61%
RETURN ON EQUITY (ROE) AVG 15Y
1.59%
RETURN ON EQUITY (ROE) AVG 20Y
3.20%
CURRENT VS TTM AVG
+60.10%
CURRENT VS 3Y AVG
+28.32%
CURRENT VS 5Y AVG
-111.71%
CURRENT VS 10Y AVG
-386.76%
CURRENT VS 15Y AVG
-2424.47%
CURRENT VS 20Y AVG
-1257.56%
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 633 covered companies
CURRENT VS SECTOR MEDIAN
+7.83%
vs the sector median at left
Myriad Genetics, Inc.
Market Cap
$409.91M
Return on Equity (ROE)
-37.05%
TTM Avg
-92.85%
3Y Avg
-51.69%
5Y Avg
-17.50%
Market Cap
$408.96M
Return on Equity (ROE)
-28.18%
TTM Avg
-0.06%
3Y Avg
10.58%
5Y Avg
10.58%
Market Cap
$408.59M
Return on Equity (ROE)
-43.14%
TTM Avg
2.19%
3Y Avg
15.11%
5Y Avg
15.11%
Market Cap
$414.54M
Return on Equity (ROE)
-80.96%
TTM Avg
-47.93%
3Y Avg
-34.61%
5Y Avg
-20.56%
Market Cap
$413.70M
Return on Equity (ROE)
-51.17%
TTM Avg
-29.16%
3Y Avg
-33.45%
5Y Avg
-16.04%
Market Cap
$415.97M
Return on Equity (ROE)
-69.06%
TTM Avg
36.89%
3Y Avg
36.89%
5Y Avg
36.89%
Market Cap
$420.45M
Return on Equity (ROE)
-15.33%
TTM Avg
-56.08%
3Y Avg
-39.28%
5Y Avg
-33.86%
Market Cap
$424.57M
Return on Equity (ROE)
-77.06%
TTM Avg
-61.48%
3Y Avg
-56.03%
5Y Avg
-55.28%
Market Cap
$393.86M
Return on Equity (ROE)
-65.99%
TTM Avg
-51.25%
3Y Avg
-81.12%
5Y Avg
-81.12%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Myriad Genetics, Inc. (MYGN) | $409.91M | -37.05% | -92.85% | -51.69% | -17.50% |
| Shoulder Innovations, Inc. (SI)vs › | $408.96M | -28.18% | -0.06% | 10.58% | 10.58% |
| Carlsmed, Inc. (CARL)vs › | $408.59M | -43.14% | 2.19% | 15.11% | 15.11% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $414.54M | -80.96% | -47.93% | -34.61% | -20.56% |
| Neurogene Inc. (NGNE)vs › | $413.70M | -51.17% | -29.16% | -33.45% | -16.04% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $415.97M | -69.06% | 36.89% | 36.89% | 36.89% |
| Prothena Corporation plc (PRTA)vs › | $420.45M | -15.33% | -56.08% | -39.28% | -33.86% |
| Rezolute, Inc. (RZLT)vs › | $424.57M | -77.06% | -61.48% | -56.03% | -55.28% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $393.86M | -65.99% | -51.25% | -81.12% | -81.12% |
| REGENXBIO Inc. (RGNX)vs › | $393.42M | -273.72% | -138.09% | -103.75% | -71.29% |
ROE
-37.1%
ROA
-17.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -37.05% |
| 2026-03-31 | -118.52% |
| 2025-12-31 | -99.43% |
| 2025-09-30 | -107.43% |
| 2025-06-30 | -101.83% |
| 2025-03-31 | -14.39% |
| 2024-12-31 | -18.16% |
| 2024-09-30 | -15.85% |
| 2024-06-30 | -20.96% |
| 2024-03-31 | -30.87% |
| 2023-12-31 | -33.62% |
| 2023-09-30 | -40.15% |
| 2023-06-30 | -33.76% |
| 2023-03-31 | -17.50% |
| 2022-12-31 | -12.64% |
| 2022-09-30 | -8.43% |
| 2022-06-30 | -1.86% |
| 2022-03-31 | -0.86% |
| 2021-12-31 | -2.81% |
| 2021-09-30 | -2.02% |
| 2021-06-30 | -6.58% |
| 2021-03-31 | -12.58% |
| 2020-12-31 | -21.12% |
| 2020-09-30 | -21.35% |
| 2020-06-30 | -21.73% |
| 2020-03-31 | -15.33% |
| 2019-12-31 | -2.43% |
| 2019-09-30 | -1.42% |
| 2019-06-30 | 0.42% |
| 2019-03-31 | 1.41% |
| 2018-12-31 | 1.64% |
| 2018-09-30 | 4.16% |
| 2018-06-30 | 12.97% |
| 2018-03-31 | 13.88% |
| 2017-12-31 | 13.86% |
| 2017-09-30 | 11.68% |
| 2017-06-30 | 2.82% |
| 2017-03-31 | 5.96% |
| 2016-12-31 | 10.22% |
| 2016-09-30 | 14.43% |
| 2016-06-30 | 18.39% |
| 2016-03-31 | 15.66% |
| 2015-12-31 | 13.95% |
| 2015-09-30 | 13.74% |
| 2015-06-30 | 12.10% |
| 2015-03-31 | 14.21% |
| 2014-12-31 | 15.90% |
| 2014-09-30 | 19.20% |
| 2014-06-30 | 24.51% |
| 2014-03-31 | 25.85% |
| 2013-12-31 | 27.78% |
| 2013-09-30 | 24.99% |
| 2013-06-30 | 20.19% |
| 2013-03-31 | 19.88% |
| 2012-12-31 | 18.72% |
| 2012-09-30 | 18.44% |
| 2012-06-30 | 17.64% |
| 2012-03-31 | 16.72% |
| 2011-12-31 | 17.41% |
| 2011-09-30 | 17.84% |
| 2011-06-30 | 17.77% |
| 2011-03-31 | 24.39% |
| 2010-12-31 | 23.74% |
| 2010-09-30 | 25.28% |
| 2010-06-30 | 27.31% |
| 2010-03-31 | 21.63% |
| 2009-12-31 | 22.18% |
| 2009-09-30 | 21.26% |
| 2009-06-30 | 19.49% |
| 2009-03-31 | 21.67% |
| 2008-12-31 | 18.58% |
| 2008-09-30 | 14.74% |
| 2008-06-30 | 11.24% |
| 2008-03-31 | -7.22% |
| 2007-12-31 | -7.67% |
| 2007-09-30 | -8.94% |
| 2007-06-30 | -10.27% |
| 2007-03-31 | -11.37% |
| 2006-12-31 | -17.90% |
| 2006-09-30 | -17.25% |
| 2006-06-30 | -15.29% |
| 2006-03-31 | -14.30% |
| 2005-12-31 | -14.19% |
| 2005-09-30 | -30.72% |
| 2005-06-30 | -29.47% |
| 2005-03-31 | -28.11% |
| 2004-12-31 | -26.75% |
| 2004-09-30 | -25.06% |
| 2004-06-30 | -23.44% |
| 2004-03-31 | -27.90% |
| 2003-12-31 | -22.26% |
| 2003-09-30 | -18.94% |
| 2003-06-30 | -15.18% |
